R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

R1制药公司完成超额认购的7750万美元A轮融资，用于推进慢性肾病患者高磷血症的首创治疗。

• Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care

• A轮由Abingworth、DaVita风险投资集团和F-Prime共同领投，Curie.Bio、SymBiosis和美国肾病护理（U.S. Renal Care）参与投资

• Partnership with Alebund Pharmaceuticals to gain exclusive global development and commercial rights outside of Greater China for AP306, a differentiated pan phosphate transporter inhibitor, the only agent blocking the active transport of phosphate

与Alebund制药合作，获得AP306的全球独家开发和商业化权利（大中华区以外），AP306是一种差异化泛磷酸盐转运蛋白抑制剂，是唯一能够阻断磷酸盐主动运输的药物。

• Advancing Phase 2b clinical development of AP306 as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis

• 推进AP306作为单一疗法用于透析慢性肾病患者的高磷血症的2b期临床开发

REDWOOD CITY, Calif., March 17, 2026-- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, today announced its launch with an oversubscribed $77.5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals, Ltd.

美国加利福尼亚州红木城，2026年3月17日 —— R1 Therapeutics, Inc（“R1”），一家专注于为肾病患者开发首创疗法的临床阶段生物制药公司，今天宣布完成超额认购的7750万美元A轮融资，并从中国Alebund Pharmaceuticals, Ltd.获得AP306在大中华区以外的全球独家开发和商业化许可。

(“Alebund”). The financing was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and U.S. Renal Care..

（“Alebund”）。本轮融资由Abingworth、F-Prime和DaVita Inc.（纽约证券交易所代码：DVA）旗下的DaVita Venture Group共同领投，Curie.Bio、SymBiosis和U.S. Renal Care也参与其中。

Proceeds from the Series A financing will fund R1's global development program of AP306 in partnership with Alebund, including a Phase 2b study planned to start later this year.

A轮融资的收益将资助R1与Alebund合作的AP306全球开发计划，其中包括预计在今年晚些时候开始的2b期研究。

AP306 is a first-in-class, pan phosphate transporter inhibitor in development as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). Whereas currently available approved phosphate lowering therapies work by inhibiting “passive” transport of phosphate through binding phosphate and other mechanisms, AP306 is distinguished as being the only agent that blocks the “active” transport of phosphate for the treatment of CKD..

AP306 是一种首创的、广谱磷酸盐转运蛋白抑制剂，正在开发作为单药疗法，用于治疗慢性肾病 (CKD) 患者的高磷血症。当前可用的已批准磷酸盐降低疗法通过结合磷酸盐和其他机制来抑制磷酸盐的“被动”运输，而 AP306 的独特之处在于，它是唯一一种通过阻断磷酸盐的“主动”运输来治疗 CKD 的药物。

The treatment of hyperphosphatemia is an important component in managing CKD patients, especially those on dialysis, yet it represents a high unmet need. More than 500,000 patients in the United States1 and four million worldwide receive dialysis,2 however more than 40% of US patients fail to achieve treatment targets.3 Uncontrolled hyperphosphatemia contributes to bone and cardiovascular disease, leading to significant risk of morbidity and mortality.4 Current phosphate binders, which have been the standard of care for 60 years, are limited by low binding capacity, high pill burden and poor gastrointestinal tolerability, contributing to poor adherence and limiting the effectiveness of these therapies.5.

治疗高磷血症是管理慢性肾病（CKD）患者，尤其是透析患者的重要组成部分，但这仍然是一个未被满足的重大需求。美国有超过50万名患者，全球有400万患者接受透析，然而超过40%的美国患者未能达到治疗目标。不受控制的高磷血症会导致骨骼和心血管疾病，造成显著的发病和死亡风险。目前的磷酸盐结合剂作为60年来的标准疗法，受到结合能力低、服药负担重以及胃肠道耐受性差的限制，导致患者依从性差，并限制了这些疗法的有效性。

AP306 has been evaluated in a Phase 2a study in dialysis patients, with results published in Kidney International Reports6 demonstrating significant reduction in serum phosphate levels with good safety and tolerability.

AP306 已在透析患者的 2a 期研究中进行了评估，结果发表在《肾脏国际报告》上，显示其能显著降低血清磷水平，且安全性和耐受性良好。

R1 is led by Co-Founder, President and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of experience in the biopharmaceutical industry and a track record of pipeline advancement and company creation. Joining Dr. Polu is fellow Co-Founder, biotech veteran, and former Chief Development Officer at SpringWorks Therapeutics, L.

R1由联合创始人、总裁兼首席执行官克里希纳·波卢博士（Krishna Polu, M.D.）领导，他是一位拥有超过20年生物制药行业经验的肾病学家，在研发管线推进和公司创建方面有着卓越记录。与波卢博士共同合作的还有另一位联合创始人、生物技术领域的资深人士以及曾在SpringWorks Therapeutics担任首席开发官的L。

Mary Smith, Ph.D., who will serve as Chief Operating Officer and lead R1’s development activities..

玛丽·史密斯博士将担任首席运营官并领导R1的开发活动。

“We are excited to be launching R1 Therapeutics in partnership with Alebund and with support from a strong, experienced syndicate including DaVita and U.S. Renal Care, recognized global providers transforming kidney care. This backing, plus a differentiated clinical-stage asset, positions us to address one of the most persistent challenges in managing patients with chronic kidney disease,” said Krishna Polu, M.D., Co-Founder, President and CEO of R1 Therapeutics.

“我们很高兴能与Alebund合作推出R1 Therapeutics，并得到包括DaVita和U.S. Renal Care在内的强大且经验丰富的财团支持，这些全球知名机构正在改变肾脏护理的格局。有了这样的支持，再加上差异化的临床阶段资产，使我们能够应对管理慢性肾病患者时最持久的挑战之一，”R1 Therapeutics联合创始人、总裁兼首席执行官Krishna Polu博士表示。

“AP306 represents a fundamentally new approach to treating hyperphosphatemia. By blocking the active transport of phosphate through three different phosphate transporters in the GI tract, initial clinical studies suggest AP306 has the potential to deliver superior efficacy with substantially lower pill burden compared to current phosphate binder therapies.

“AP306 代表了一种治疗高磷血症的全新方法。通过阻断胃肠道中三种不同的磷酸盐转运蛋白的活性运输，初步临床研究表明，与目前的磷酸盐结合剂疗法相比，AP306 具有提供更优疗效的潜力，同时药片负担大幅降低。”

If successful, AP306 should redefine the class of phosphate lowering therapies and become the treatment of choice for the management of hyperphosphatemia.”.

如果成功，AP306应该会重新定义磷降低疗法的类别，并成为治疗高磷血症的首选方法。

“R1 Therapeutics brings together an exceptional leadership team with deep nephrology expertise and a clear vision for advancing AP306,” said Gavin Xia, CEO of Alebund Pharmaceuticals. “This asset addresses a significant unmet need in a large, underserved patient population. We are delighted to partner with R1 Therapeutics to develop AP306 globally and improve outcomes for the millions of CKD patients struggling with inadequate phosphate control.”.

“R1 Therapeutics汇聚了一支拥有深厚肾病学专业知识和推进AP306清晰愿景的卓越领导团队，”Alebund Pharmaceuticals首席执行官Gavin Xia表示，“该资产满足了广大未被充分服务患者群体中的重大未满足需求。我们很高兴与R1 Therapeutics合作，在全球范围内开发AP306，并改善数百万因磷酸盐控制不佳而苦苦挣扎的慢性肾病患者的治疗效果。”

R1’s Board of Directors will be comprised of Andrew Sinclair, Ph.D., Managing Director at Abingworth; Tom Musgrave, Vice President, Pharma Strategy at DaVita Venture Group; Chong Xu, Ph.D., Partner at F-Prime; Ben Auspitz, Managing Partner at Curie.Bio; Steve Landau, M.D., Independent Director; and Krishna Polu, M.D., Co-Founder, President and CEO of R1..

R1的董事会将由Abingworth的董事总经理Andrew Sinclair博士、DaVita风险投资集团制药战略副总裁Tom Musgrave、F-Prime的合伙人Chong Xu博士、Curie.Bio的管理合伙人Ben Auspitz、独立董事Steve Landau博士以及R1的联合创始人、总裁兼首席执行官Krishna Polu博士组成。

AP306 (previously known as EOS789) was originally discovered and developed by Chugai Pharmaceutical Co., Ltd. and subsequently licensed to Alebund Pharmaceuticals. Investigational New Drug (IND) applications to support AP306’s clinical development are open in both the United States and China.

AP306（之前称为EOS789）最初由中外制药株式会社发现并开发，随后授权给Alebund制药公司。支持AP306临床开发的新药研究申请（IND）已在美国和中国开放。

About R1 Therapeutics

关于R1治疗学

R1 Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of first-in-class therapies for patients with kidney disease. Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis, a condition associated with serious bone and cardiovascular complications and poorer outcomes when phosphate remains uncontrolled.

R1 Therapeutics是一家临床阶段的生物制药公司，专注于为肾病患者开发首创疗法。其主要项目AP306针对接受透析的慢性肾病患者的高磷血症，这种疾病在磷酸盐得不到控制时会引发严重的骨骼和心血管并发症，并导致更差的预后。

AP306 is a first-in-class pan phosphate active transport inhibitor designed to block three key phosphate transporters in the gut, with the potential to deliver rapid and effective phosphate lowering with a significantly reduced treatment burden. R1 has licensed exclusive global rights outside of Greater China to AP306 from Alebund Pharmaceuticals and is advancing a global Phase 2b development program.

AP306 是一种首创的泛磷酸盐主动转运抑制剂，旨在阻断肠道中的三个关键磷酸盐转运蛋白，具有快速有效降低磷酸盐水平的潜力，并显著减轻治疗负担。R1 已从阿莱邦制药公司获得 AP306 在大中华区以外的全球独家权利，并正在推进一项全球性的 2b 期开发计划。

R1 launched with an oversubscribed $77.5 million Series A financing in March 2026 co-led by Abingworth, DaVita Venture Group, and F-Prime, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. For more information, visit www.r1therapeutics.com and follow R1 on LinkedIn..

R1于2026年3月完成了由Abingworth、DaVita Venture Group和F-Prime共同领投的7750万美元超额认购的A轮融资，Curie.Bio、SymBiosis和U.S. Renal Care也参与其中。欲了解更多信息，请访问www.r1therapeutics.com并在LinkedIn上关注R1。

About Alebund Pharmaceuticals

关于阿莱邦制药公司

Alebund was founded in Shanghai in 2018. The Company focuses on the discovery, development, manufacturing, and commercialization of novel therapies primarily for kidney diseases and their complications, as well as other chronic conditions, to bring better therapeutic options to patients in China and globally.

阿勒布恩德于2018年在上海成立。公司专注于发现、开发、制造和商业化主要用于治疗肾病及其并发症以及其他慢性疾病的新型疗法，为中国的患者乃至全球的患者带来更好的治疗选择。

Alebund has built a diversified and balanced pipeline of seven drug candidates and one commercialized product (Mircera®) targeting a broad range of renal indications, including chronic kidney disease (CKD) and CKD complications, such as hyperphosphatemia, renal anemia, IgA nephropathy, diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and autosomal dominant polycystic kidney disease (ADPKD).

Alebund已经建立了多样且均衡的管线，包含七种候选药物和一种已上市产品（Mircera®），针对广泛的肾脏疾病适应症，包括慢性肾病（CKD）及其并发症，如高磷血症、肾性贫血、IgA肾病、糖尿病肾病、局灶节段性肾小球硬化（FSGS）以及常染色体显性多囊肾病（ADPKD）。

Alebund has completed the construction of its manufacturing site in Yangzhou that will supply both drug substance and drug products of its product candidates upon commercial launch. Alebund has also established a dedicated in-house commercialization team in China responsible for promoting the renal products..

阿莱邦德已经完成了其扬州生产基地的建设，该基地将在产品上市时供应其候选产品的原料药和制剂。阿莱邦德还在中国建立了一支专门的内部商业化团队，负责推广其肾脏产品。

About Abingworth

关于Abingworth

Abingworth is a leading transatlantic life sciences investment firm and part of the global investment firm Carlyle. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in approximately 200 life science companies, leading to over 50 mergers and acquisitions and more than 75 IPOs.

Abingworth是一家领先的大西洋两岸生命科学投资公司，也是全球投资公司凯雷集团的一部分。Abingworth通过向打造世界级企业的顶级管理团队提供资金和专业知识，帮助将尖端科学转化为新型药物。自1973年以来，Abingworth已投资了约200家生命科学公司，促成了50多起并购和75多次首次公开募股（IPO）。

Abingworth’s therapeutics-focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and New York. For more information, please visit www.abingworth.com..

Abingworth的治疗学相关投资分为三类：种子和早期阶段、开发阶段以及临床共同开发。Abingworth通过其在伦敦、门洛帕克（加利福尼亚）和纽约的办事处，为旗下投资组合公司提供经验丰富的专业团队支持。欲了解更多信息，请访问www.abingworth.com。

About F-Prime

关于F-Prime

F-Prime is a global venture capital firm investing in healthcare and technology. For over 50 years, our venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies.

F-Prime 是一家全球风险投资公司，专注于医疗保健和科技领域的投资。在过去的 50 多年里，我们的风险投资团队有幸支持了许多杰出的企业家，帮助他们打造具有开创性的公司。

With over $4.8 billion under management and a global portfolio of over 400 companies, we champion those dedicated to creating positive change in the world. In healthcare, we focus on therapeutics, medtech and healthtech and services in a stage-agnostic fashion. Our healthcare fund has created or co-created over 35 companies including Denali, Beam, Innovent, and Orchard and has helped build many others including Blueprint Medicines, Iora Health, PatientPing, Devoted and Ultragenyx.

管理着超过48亿美元的资金，拥有全球范围内超过400家公司的投资组合，我们支持那些致力于为世界创造积极变革的人。在医疗保健领域，我们专注于治疗、医疗技术和健康技术以及服务，且不区分发展阶段。我们的医疗基金已经创建或共同创建了超过35家公司，包括Denali、Beam、Innovent和Orchard，并帮助建立了许多其他公司，包括Blueprint Medicines、Iora Health、PatientPing、Devoted和Ultragenyx。

F-Prime portfolio companies have seen more than 35 products and drugs approved by regulatory agencies worldwide. Our team of investors, engineers, doctors and scientists is committed to bringing the insight, domain expertise and relationships required to help our companies make a transformational impact..

F-Prime 投资组合公司已经看到全球监管机构批准了35种以上的产品和药物。我们的投资者、工程师、医生和科学家团队致力于带来洞察力、领域专业知识和关系，帮助我们的公司产生变革性影响。

F-Prime has offices in Cambridge, MA, San Francisco, CA, and London, UK. Please visit fprimecapital.com and follow us on Twitter and LinkedIn.

F-Prime 在马萨诸塞州剑桥、加利福尼亚州旧金山和英国伦敦设有办事处。请访问 fprimecapital.com 并在 Twitter 和 LinkedIn 上关注我们。

About DaVita Inc.

关于DaVita公司

DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 25 years. DaVita cares for patients at every stage and setting along their kidney health journey – from slowing the progression of kidney disease to helping support transplantation.

DaVita（纽约证券交易所代码：DVA）是一家致力于转变医疗交付模式以提高全球患者生活质量的医疗服务提供商。作为一家全面的肾脏护理服务提供者，DaVita 在临床质量和创新方面已经引领行业超过25年。DaVita 在患者肾脏健康的每一个阶段和场景中提供护理——从减缓肾脏疾病的发展到帮助支持移植。

This includes ensuring they are supported at home, in dialysis centers, in the hospital and in skilled nursing facilities. As of December 31, 2025, DaVita served approximately 295,000 patients at 3,242 outpatient dialysis centers, of which 2,657 centers were located in the United States and 585 centers were located in 14 other countries worldwide.

这包括确保他们在家中、在透析中心、在医院以及在专业护理机构中得到支持。截至2025年12月31日，DaVita在3,242家门诊透析中心为大约295,000名患者提供服务，其中2,657家中心位于美国，585家中心分布在世界其他14个国家。

DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About..

DaVita 减少了住院人数，改善了死亡率，帮助提高了医疗资源的可及性，并通过协作推动肾病护理领域采纳更高质量的护理标准，为全球所有患者服务。欲了解更多信息，请访问 DaVita.com/About。

About Curie.Bio

关于Curie.Bio

Curie.Bio is a $1.25B global venture capital firm that helps founders discover and develop important new medicines. The firm partners with founders and management teams by investing in existing companies, creating focused spinouts, and building companies from scratch. Curie.Bio’s Seed model uniquely combines capital with hands-on drug development, operating as both a drug discovery copilot and an investor.

Curie.Bio是一家价值12.5亿美元的全球风险投资公司，致力于帮助创始人发现和开发重要的新药物。该公司通过投资现有公司、创建专注的分拆公司以及从零开始组建公司，与创始人和管理团队合作。Curie.Bio的种子模型将资本与实际的药物开发相结合，既充当药物发现的协作伙伴，又作为投资者运作。

Its 100+ person team of experienced drug hunters, drug makers, and operators works closely with founders on a day-to-day basis to improve decision-making and increase the probability of success. Curie.Bio’s Breakout Fund supplies translational capital to support more mature companies through key clinical and regulatory milestones.

其由100多名经验丰富的药物猎手、药物制造者和运营人员组成的团队与创始人密切合作，以提高决策质量并增加成功的可能性。Curie.Bio的突破基金提供转化资本，支持较成熟的企业通过关键的临床和监管里程碑。

Learn more at www.curie.bio..

请访问 www.curie.bio 了解更多信息。

About SymBiosis Capital Management, LLC

关于共生资本管理有限责任公司

SymBiosis is an investment firm focused on advancing biotherapeutics innovations for serious and life-threatening diseases. The firm is an active, global investor in groundbreaking medicines across many disease areas and financing stages, with a focus on programs in, or about to enter, human trials.

共生资本是一家专注于推进严重和危及生命疾病的生物治疗创新的投资公司。该公司是许多疾病领域和融资阶段的突破性药物的积极全球投资者，重点关注即将进入或已经进入人体试验阶段的项目。

SymBiosis invests through a series of long-duration investment vehicles with significant capacity for new investments. For more information, please visit www.symbiosis.vc or follow us on LinkedIn..

共生投资通过一系列长期投资工具进行投资，这些工具具有显著的新投资能力。欲了解更多信息，请访问 www.symbiosis.vc 或在LinkedIn上关注我们。

About U.S. Renal Care

关于美国肾病护理

U.S. Renal Care, the largest privately held and fastest-growing dialysis provider in the nation, partners with nephrologists to care for more than 37,000 people living with kidney disease across 32 states in the U.S. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence – delivering the best experience and outcomes for its patients.

美国肾病护理公司（U.S. Renal Care）是全国最大的私人持有且增长最快的透析服务提供商，与肾病学家合作，在美国32个州为超过37,000名肾病患者提供护理。自2000年以来，美国肾病护理公司一直是临床质量、创新和运营卓越的领导者，为患者提供最佳的体验和治疗效果。

Visit USRenalCare.com to learn more..

访问USRenalCare.com以了解更多信息。

References

参考文献

1. United States Renal Data System. 2024. USRDS 2024 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

1. 美国肾脏数据系统。2024。USRDS 2024年度数据报告。国立卫生研究院，国家糖尿病、消化和肾脏疾病研究所。

2. Mark, Patrick B et al. 2025. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, Volume 406, Issue 10518, 2461 - 2482

2. Mark, Patrick B 等。2025。1990年至2023年成人慢性肾病的全球、区域和国家负担及其可归因风险因素：2023年全球疾病负担研究的系统分析。《柳叶刀》，第406卷，第10518期，2461 - 2482页。

3. United States Renal Data System. 2024. USRDS 2024 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

3. 美国肾脏数据系统。2024。USRDS 2024年度数据报告。国立卫生研究院，国立糖尿病、消化与肾脏疾病研究所。

4. Ketteler M, Block GA, Evenepoel P, et al. 2017 Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017;92:26–36

4. Ketteler M, Block GA, Evenepoel P, 等。2017 KDIGO慢性肾脏病-矿物质和骨病（CKD-MBD）指南更新的2017年执行摘要：哪些内容改变了以及为何重要。《肾脏国际》。2017；92:26–36。

5. Fissel R et al. 2016 Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. Hemodial Int. 2016 January ; 20(1): 38–49. doi:10.1111/hdi.12315

5. Fissel R 等。2016 年 磷结合剂药片负担、患者报告的不依从性及矿物质骨病标志物：来自DOPPS的研究结果。《国际血液透析杂志》。2016年1月；20(1): 38–49。doi:10.1111/hdi.12315

6. Wang L, Zuo L, Shi M, et al. 2025 A pan-inhibitor of phosphate transporters AP306 in hemodialysis patients. Kidney Int Rep. 2025;10(4):1143–1151. doi:10.1016/S2468-0249(25)00063-4

6. 王磊，左亮，史明，等。2025年 AP306——一种用于血液透析患者的磷酸盐转运蛋白的泛抑制剂。《肾脏国际报告》，2025；10(4): 1143–1151。doi:10.1016/S2468-0249(25)00063-4